Proactive – Daniel Tillett on Racura Oncology’s drug advancements
Proactive – Daniel Tillett on Racura Oncology’s drug advancements
Racura CEO and Managing Director Dr Daniel Tillett speaks with Proactive about the company’s development of a reformulated cancer drug aimed at improving chemotherapy treatment. Dr Tillett discussed the challenges of chemotherapy, including severe...
Proactive: Oncology market projected to soar in 2025 and beyond
Proactive: Oncology market projected to soar in 2025 and beyond
Proactive reports on the outlook of the oncology therapeutics market, naming Racura Oncology, alongside its peer companies, one of the most promising to look out for. Read the full article via this link....
Road to 2025: Racura on track with clinical trials
Road to 2025: Racura on track with clinical trials
Stockhead’s Road to 2025 video series highlights companies’ key 2024 achievements and the routes they’re plotting towards a successful year ahead. In this episode, Fraser Palamara takes a look at Racura Oncology (ASX:RAC)....
Behind Racura Oncology’s quest to prevent chemo from being worse than the disease
Behind Racura Oncology’s quest to prevent chemo from being worse than the disease
Racura Oncology is reformulating bisantrene (RAC-220) to prevent chemotherapy-induced heart damage, with a phase 1 cardioprotection trial planned for early 2025. The trial will enroll 25-40 patients across multiple sites. The company has also...
The Australian: Racura Oncology bolsters leadership with key appointment
The Australian: Racura Oncology bolsters leadership with key appointment
As seen in The Australian, Dr Megan Baldwin joins the Racura board as Non-Executive Director. Dr Baldwin is a seasoned biotech executive with more than 25 years of experience. She is the Founder and...
Proactive: Racura Oncology secures A$5.25 million R&D tax rebate for FY2024
Proactive: Racura Oncology secures A$5.25 million R&D tax rebate for FY2024
Proactive reports on Racura’s R&D tax rebate and clinical progress made in FY 2024. Read the full article here....
The Australian: Racura submits key ethics application for phase I cancer trial
The Australian: Racura submits key ethics application for phase I cancer trial
Conducted in two stages, the Phase 1 clinical trial will examine the safety and tolerability of the reformulated bisantrene, RC220, in particular the drug’s cardioprotective ability when used in combination with doxorubicin, a form...
Proactive: Racura Oncology submits human ethics for RC220 Phase 1 solid tumour trial
Proactive: Racura Oncology submits human ethics for RC220 Phase 1 solid tumour trial
Racura Oncology Ltd (ASX:RAC, OTC:RAONF) has taken another key step toward a Phase 1 trial in solid tumour patients using RC220 bisantrene by submitting an application for an ethics and regulatory package to Bellberry Human...
Proactive: Racura Oncology advances RNA epigenetics with FTO drug discovery at Monash
Proactive: Racura Oncology advances RNA epigenetics with FTO drug discovery at Monash
Racura CEO Dr Daniel Tillett joins Proactive’s Tylah Tully to discuss the FTO drug discovery program the company has concluded at Monash University’s Fragment Platform (MFP). Watch the full interview below and for the...
ausbiz: Racing ahead – successful trial & board revamp at Racura Oncology
ausbiz: Racing ahead – successful trial & board revamp at Racura Oncology
CEO and MD Dr Daniel Tillett joined ausbiz post the release of September Quarterly Activity Report, reaffirming the company’s strong funding position, clinical pipeline, and noting changes in the Board and Management team. Watch...
